Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Øyvind Hjertner

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Medical Oncology (Northwood, London, England)|February 17, 2007
Bone disease in multiple myelomaØyvind Hjertner, Therese Standal, Magne Børset, et al.
European Journal of Haematology|January 17, 2021
Patterns of previous and secondary malignancies in patients with multiple myelomaØystein O Langseth, Tor Å Myklebust, Tom B Johannesen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|January 19, 2013
Serotonin in blood: assessment of its origin by concomitant determination of β-thromboglobulin (platelets) and chromogranin A (enterochromaffin cells)Fatemeh Zeinali, Reidar Fossmark, Øyvind Hauso, et al.
British Journal of Haematology|May 6, 2020
Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017Øystein O Langseth, Tor Å Myklebust, Tom B Johannesen, et al.
European Journal of Haematology|February 20, 2022
Risk of multiple myeloma and other malignancies among first- and second-degree relatives of patients with multiple myeloma: A population-based studyØystein O Langseth, Tor Å Myklebust, Tom B Johannesen, et al.
Resuscitation|August 24, 2010
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrestThor Wilhelm Bjelland, Øyvind Hjertner, Pål Klepstad, et al.
Blood|September 28, 2002
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsTherese Standal, Carina Seidel, Øyvind Hjertner, et al.
Ejhaem|January 27, 2025
Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and DexamethasoneTobias S Slørdahl, Frida Bugge Askeland, Margrete Sofie Sætre Hanssen, et al.
European Journal of Haematology|March 13, 2012
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyMartin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Medical Oncology (Northwood, London, England)|February 17, 2007
Bone disease in multiple myelomaØyvind Hjertner, Therese Standal, Magne Børset, et al.
European Journal of Haematology|January 17, 2021
Patterns of previous and secondary malignancies in patients with multiple myelomaØystein O Langseth, Tor Å Myklebust, Tom B Johannesen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|January 19, 2013
Serotonin in blood: assessment of its origin by concomitant determination of β-thromboglobulin (platelets) and chromogranin A (enterochromaffin cells)Fatemeh Zeinali, Reidar Fossmark, Øyvind Hauso, et al.
British Journal of Haematology|May 6, 2020
Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017Øystein O Langseth, Tor Å Myklebust, Tom B Johannesen, et al.
European Journal of Haematology|February 20, 2022
Risk of multiple myeloma and other malignancies among first- and second-degree relatives of patients with multiple myeloma: A population-based studyØystein O Langseth, Tor Å Myklebust, Tom B Johannesen, et al.
Resuscitation|August 24, 2010
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrestThor Wilhelm Bjelland, Øyvind Hjertner, Pål Klepstad, et al.
Blood|September 28, 2002
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsTherese Standal, Carina Seidel, Øyvind Hjertner, et al.
Ejhaem|January 27, 2025
Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and DexamethasoneTobias S Slørdahl, Frida Bugge Askeland, Margrete Sofie Sætre Hanssen, et al.
European Journal of Haematology|March 13, 2012
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyMartin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.
Pageof 1